NQTIPS: The Efficacy and Safety of Silodosin Singly or Combined With Ningmitai Capsules in the Treatment of Benign Prostatic Hyperplasia

Sponsor

Xintian Pharmaceutical (Industry)

Overall Status

Recruiting

CT.gov ID

NCT05551221

Collaborator

(none)

312

Enrollment

Locations

Arms

53.5

Anticipated Duration (Months)

Patients Per Site

0.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Objective: To evaluate the efficacy and safety of Ningmitai Capsules and Silodosin Capsules in the treatment of Benign Prostatic Hyperplasia (BPH) with Lower Urinary Tract Symptoms (LUTS) compared with Tamsulosin Hydrochloride Sustained Release Capsules.

Study design: A multicenter, prospective, randomized, double-blind, positive controlled clinical study.

Interventions:

Group A: Oral Tamsulosin Hydrochloride Capsules and Ningmitai Capsules placebo for 12 weeks.

Group B: Oral l Silodosin Capsules and Ningmitai Capsules placebo for 12 weeks. Group C: Oral l Silodosin Capsules and Ningmitai Capsules for 12 weeks.

Condition or Disease	Intervention/Treatment	Phase
Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms	Drug: Silodosin Capsules Drug: Ningmitai capsule Drug: Tamsulosin	Phase 4

Detailed Description

Sample size: 312

Study Design

Study Type:

Interventional

Anticipated Enrollment :

312 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

Group A: Oral Tamsulosin Hydrochloride Capsules and Ningmitai Capsules placebo for 12 weeks. Group B: Oral l Silodosin Capsules and Ningmitai Capsules placebo for 12 weeks. Group C: Oral l Silodosin Capsules and Ningmitai Capsules for 12 weeks.Group A: Oral Tamsulosin Hydrochloride Capsules and Ningmitai Capsules placebo for 12 weeks. Group B: Oral l Silodosin Capsules and Ningmitai Capsules placebo for 12 weeks. Group C: Oral l Silodosin Capsules and Ningmitai Capsules for 12 weeks.

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

The Efficacy and Safety of Silodosin Singly or Combined With Ningmitai Capsules in the Treatment of Benign Prostatic Hyperplasia (BPH) Complicated With Lower Urinary Tract Symptoms (LUTS) -A Multicenter, Prospective, Randomized, Double-blind, Positive Controlled Study

Actual Study Start Date :

Jul 18, 2022

Anticipated Primary Completion Date :

Dec 31, 2023

Anticipated Study Completion Date :

Dec 31, 2026

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Tamsulosin Hydrochloride Capsules combine with Ningmitai Capsules placebo Patients take tamsulosin hydrochloride capsules (1 tablet each time, once daily) and Ningmitai capsules placebo (0.38 g/capsule, 4 capsules/time, tid.)	Drug: Tamsulosin Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.
Experimental: Silodosin Capsules combine with Ningmitai Capsules placebo Patients take Silodosin Capsules ( Qianweitai®, 4mg/capsule, 1 capsule/time, bid, after breakfast and dinner) and Ningmitai capsules placebo (0.38 g/capsule, 4 capsules/time, tid).	Drug: Silodosin Capsules Silodosin is a α1A-adrenergic receptor antagonist which can relax the smooth muscle of bladder and prostate, relieves the dynamic obstruction of bladder outlet, and improves the lower urinary tract symptoms caused by BPH. The instruction of Silodosin Capsule (Qianweitai®) is 4mg/capsule，1 capsule/time, bid, after breakfast and dinner. Other Names: Qianweitai
Experimental: Silodosin Capsules combine with Ningmitai Capsules Patients take Silodosin Capsules ( Qianweitai®, 4mg/capsule, 1 capsule/time, bid, after breakfast and dinner) and Ningmitai capsules (Ningmitai®, 0.38 g/capsule, 4 capsules/time, tid).	Drug: Silodosin Capsules Silodosin is a α1A-adrenergic receptor antagonist which can relax the smooth muscle of bladder and prostate, relieves the dynamic obstruction of bladder outlet, and improves the lower urinary tract symptoms caused by BPH. The instruction of Silodosin Capsule (Qianweitai®) is 4mg/capsule，1 capsule/time, bid, after breakfast and dinner. Other Names: Qianweitai Drug: Ningmitai capsule Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid. Other Names: Ningmitai

Arm

Intervention/Treatment

Active Comparator: Tamsulosin Hydrochloride Capsules combine with Ningmitai Capsules placebo

Patients take tamsulosin hydrochloride capsules (1 tablet each time, once daily) and Ningmitai capsules placebo (0.38 g/capsule, 4 capsules/time, tid.)

Drug: Tamsulosin

Tamsulosin is α1A-adrenergic receptor which has used in treatment of BPH for few years. The instruction of Tamsulosin Capsule is 1 tablet at a time, 1 time a day.

Experimental: Silodosin Capsules combine with Ningmitai Capsules placebo

Patients take Silodosin Capsules ( Qianweitai®, 4mg/capsule, 1 capsule/time, bid, after breakfast and dinner) and Ningmitai capsules placebo (0.38 g/capsule, 4 capsules/time, tid).

Drug: Silodosin Capsules

Silodosin is a α1A-adrenergic receptor antagonist which can relax the smooth muscle of bladder and prostate, relieves the dynamic obstruction of bladder outlet, and improves the lower urinary tract symptoms caused by BPH. The instruction of Silodosin Capsule (Qianweitai®) is 4mg/capsule，1 capsule/time, bid, after breakfast and dinner.

Other Names:

Qianweitai

Experimental: Silodosin Capsules combine with Ningmitai Capsules

Patients take Silodosin Capsules ( Qianweitai®, 4mg/capsule, 1 capsule/time, bid, after breakfast and dinner) and Ningmitai capsules (Ningmitai®, 0.38 g/capsule, 4 capsules/time, tid).

Drug: Silodosin Capsules

Other Names:

Qianweitai

Drug: Ningmitai capsule

Ningmitai Capsule (Ningmitai®) is Traditional Chinese Medicine which has already used in treatment of urinary system disease (eg. CPPS, BPH) in China for more than twenty years. The instruction of Ningmitai Capsule is 0.38g/capsule, 4 capsule/time, tid.

Other Names:

Ningmitai

Outcome Measures

Primary Outcome Measures

International Prostate Symptom Score（IPSS） [12 week]
Changes of IPSS scores at the 12th week of treatment compared with baseline scores. The scores of the scale ranged from 0 to 35. The higher the score, the more severe the symptoms are.

Secondary Outcome Measures

International Prostate Symptom Score（IPSS） total score [1, 2, 4 and 8 weeks]
Changes of IPSS scores at 1, 2, 4 and 8 weeks after treatment compared with baseline scores. The scores of the scale ranged from 0 to 35. The higher the score, the more severe the symptoms are.
IPSS Stimulus score [1, 2, 4 ,8 and 12 weeks]
IPSS Stimulation Score at 1, 2, 4, 8, 12 weeks (Sum of Question 2, 4, 7) compared with baseline. The scores of the scale ranged from 0 to 15. The higher the score, the more severe the symptoms are.
IPSS obstruction score [1, 2, 4 ,8 and 12 weeks]
Changes of IPSS obstruction score (sum of question 1, 3, 5, 6) at 1, 2, 4, 8, 12 weeks after treatment compared with baseline. The scores of the scale ranged from 0 to 20. The higher the score, the more severe the symptoms are.
IPSS total score severity [12 week]
Proportion of patients with IPSS total score severity decreased by at least one grade at 12 weeks. The scores of the scale were divided into three grades: mild (0-7), moderate (8-19) and severe (20-35).
Quality of life (QoL) score [4, 8 and 12 weeks]
Changes in scores at 4, 8 and 12 weeks of treatment compared with baseline.The scores of the scale ranged from 0 to 6. The higher the score, the more severe the symptoms are.
Maximum urinary flow rate (Qmax) [12 weeks]
The change of Qmax at 12 weeks of treatment compared with baseline.
Residual urine volume (PVR) [12 weeks]
Changes of PVR at 12 weeks of treatment compared with baseline.
Prostate specific antigen (PSA) [12 weeks]
Changes of PSA at 12 weeks of treatment compared with baseline.
Prostate volume (PV) [12 weeks]
Changes of PV at 12 weeks of treatment compared with baseline.
Patient response rate [12 weeks]
Patient response rate is defined as the proportion of patients whose IPSS total score decreased by ≥ 25% and Qmax increased by ≥ 30% compared with baseline value after treatment.
Proportion of patients with BPH clinical progression [12 weeks]
Clinical progress is defined as the first occurrence of one of the following two conditions during the trial: Acute urinary retention (AUR); Clinical diagnosis requires surgical treatment of BPH.

Eligibility Criteria

Criteria

Ages Eligible for Study:

60 Years to 80 Years

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

Inclusion Criteria:

Male Subjects aged 60 ～ 80 years, clinically diagnosed as benign prostatic hyperplasia.
Has an IPSS score ≥ 8 points at Screening and Baseline.
Has a 4 ≤ Qmax ≤ 15 ml/s when urination volume > 150 ml.
Has a prostate volume (PV) ≥ 30 ml by ultrasound examination.
Subjects who can read, understand, and complete the research questionnaire.
Subjects willing to participate voluntarily in this clinical trial, give informed consent and sign informed consent.

Exclusion Criteria:

Subjects with prostate cancer or other malignant tumors.
Subjects have serum tPSA > 10ng/ml, or 4 ≤ tPSA ≤ 10ng/ml while fPSA/tPSA < 0.16 times.
Subjects suffered from other diseases causing dysuria, such as bladder neck spasm, urethral stricture, neurogenic bladder dysfunction, etc.
Subjects have suffered from acute urinary retention, or complicated with gross hematuria, urinary tract infection, bladder stones, secondary upper urinary tract hydronephrosis, urinary incontinence, renal insufficiency and other Subjects that researchers believe meet the surgical indications.
Subjects have undergone prostate surgery, microwave therapy, urethral dilatation or acute urinary retention catheterization or other invasive procedures.
Subjects have residual urine volume (PVR) > 100ml, or those who may have urinary retention and need catheterization.
Subjects who took α receptor blockers, traditional Chinese medicine or botanical drugs for treating BPH within two weeks before participating this clinical trial.
Subjects who take 5α reductase inhibitor or other antiandrogen therapy drugs within half a year before participating this clinical trial.
Subjects who need to take drugs prohibited in this study or adopt prohibited treatment methods during treatment.
Subjects who Complicated with severe cardiovascular and cerebrovascular diseases, respiratory diseases, blood diseases, liver and kidney diseases.
There are significant abnormalities in clinical or laboratory examination indexes of patients, such as ALT and AST ≥ 2.5 times of the upper limit of reference value, creatinine (Scr) > 1.5 times of the upper limit of reference value, or poor blood glucose control (fasting blood glucose FPG ≥ 10 mmol/L).
Subjects who are allergic to the drugs or ingredients used in the test definitely.
Any otherSubjects in the opinion of researchers is not suitable for inclusion.

Contacts and Locations

Locations

	Site	City	State	Country
1	Beijing Tiantan Hospital, Capital Medical University	Beijing	Beijing	China
2	Beijing Tongren Hospital, Capital Medical University	Beijing	Beijing	China
3	The First Affiliated Hospital of Guangzhou Medical University	Guangzhou	Guangdong	China
4	Peking University Shenzhen Hospital	Shenzhen	Guangdong	China
5	The Central Hospital Of WUHAN	Wuhan	Hubei	China
6	Wuhan No.1 Hospital	Wuhan	Hubei	China
7	The Second Affiliated Hospital of Soochow University	Suzhou	Jiangsu	China
8	Wuxi No.2 People's Hospital	Wuxi	Jiangsu	China